Application of side-to-side anastomosis of the lesser curvature of stomach and jejunum in gastric bypass

Table 4 Diabetes mellitus parameters in patients combined with/without anti-diabetemedications after Laparoscopic Roux-en-Y gastric bypass surgery n (%)

HbA1c level	Preop (n = 77)	3 mo postop. (n = 77)	6 mo postop. (n = 77)	12 mo postop. (n = 56)	24 mo postop. (n = 33)
Without anti-diabetes	6 (7.8)	54 (70.1)	56 (72.7)	47 (83.9)	26 (78.8)
medications
HbA1c < 7.0%	3 (3.9)	51 (66.2)	54 (70.1)	45 (80.4)	22 (66.7)
HbA1c ≤ 6.5%	1 (1.3)	47 (61.0)	49 (63.6)	42 (75)	21 (63.6)
HbA1c ≤ 6.0%	0 (0)	34 (44.2)	37 (48.1)	36 (64.3)	15 (45.5)
With anti-diabetes	71 (92.2)	23 (29.9)	21 (27.3)	9 (16.1)	7 (21.2)
medications
HbA1c < 7.0%	15 (19.5)	13 (16.9)	10 (13.0)	5 (8.9)	5 (15.1)
HbA1c ≤ 6.5%	9 (11.7)	9 (11.7)	8 (10.4)	3 (5.4)	4 (12.1)
HbA1c ≤ 6.0%	4 (5.2)	3 (3.9)	3 (3.9)	3 (5.4)	1 (3.0)

The percentage of patients who maintained HbA1c (%) < 6.5% without antidiabeticmedicine were 61.0%, 63.6%, 75.0%, and 63.6% after 3, 6, 12, and 24 mo of surgery. T2DM parameters were significantly improved compared with preoperative baselines. T2DM: Diabetes mellitus; LRYGB: Laparoscopic Roux-en-Y gastric bypass; HbA1c: Glycosylated hemoglobin.